Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 84.5% in December

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 187,800 shares, an increase of 84.5% from the November 30th total of 101,800 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 6,130,000 shares, the short-interest ratio is presently 0.0 days.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $0.24 on Friday. The stock has a market capitalization of $14.50 million, a PE ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.68. The business has a 50 day simple moving average of $0.28 and a two-hundred day simple moving average of $0.45.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on APTO. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a research note on Tuesday, December 10th. StockNews.com began coverage on shares of Aptose Biosciences in a research report on Monday, December 23rd. They set a “hold” rating for the company.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.